Mga Batayang Estadistika
| CIK | 1760764 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to G Medical Innovations Holdings Limited
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| July 22, 2024 |
G Medical Innovations Holdings Ltd. 5 Oppenheimer Street Rehovot 76701015 Israel G Medical Innovations Holdings Ltd. 5 Oppenheimer Street Rehovot 76701015 Israel July 22, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Nicholas O’ Leary Re: G Medical Innovations Holdings Ltd. Request for Withdrawal of Registration Statement on Form F-1 File No. 333-273484 Ladies and Gentlemen: Pursuant to Rule |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 3) Under the Securities Exchange Act of 1934 G Medical Innovations Holdings Ltd. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G39462141 (CUSIP Number) Jonathan B. Rubini P.O. Box 202845 Anchorage, Alaska 99520-2845 (Name, Address and Telephone Number o |
|
| April 12, 2024 |
AMENDED AND RESTATED SECURITIES PURCHASE AGREEMENT EX-99.6 2 ea020374301ex99-6gmed.htm AMENDED 2023 SPA Exhibit 99.6 AMENDED AND RESTATED SECURITIES PURCHASE AGREEMENT This Amended and Restated Securities Purchase Agreement (this “Agreement”), dated as of April 11, 2024, comes to correct and replace the Securities Purchase Agreement dated as of September 29, 2023 (the “Original Agreement”), between G Medical Innovations Holdings Ltd., a Cayman Isl |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2) Under the Securities Exchange Act of 1934 G Medical Innovations Holdings Ltd. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G39462141 (CUSIP Number) Jonathan B. Rubini P.O. Box 202845 Anchorage, Alaska 99520-2845 (Name, Address and Telephone Number o |
|
| December 18, 2023 |
Exhibit 3.1 THE COMPANIES ACT (AS REVISED) OF THE CAYMAN ISLANDS EXEMPTED COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF G MEDICAL INNOVATIONS HOLDINGS LTD. (adopted by Special Resolution passed on December 15, 2023) THE COMPANIES ACT (AS REVISED) OF THE CAYMAN ISLANDS EXEMPTED COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF G M |
|
| December 18, 2023 |
6-K 1 ea190180-6kgmedical.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2023 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English |
|
| November 29, 2023 |
Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. |
|
| November 29, 2023 |
Exhibit 99.2 G MEDICAL INNOVATIONS HOLDINGS LTD. (Incorporated in the Cayman Islands with limited liability) (NASDAQ: GMVD) PROXY STATEMENT EXTRAORDINARY GENERAL MEETING To Be Held on 15 December 2023 This Proxy Statement is furnished to the members (“Shareholders”) of record at the close of business on 28 November 2023 (the “Record Date”) of G Medical Innovations Holdings Ltd. (“we” or the “Compa |
|
| November 29, 2023 |
Exhibit 99.1 NOTICE OF EXTRAORDINARY GENERAL MEETING The Extraordinary General Meeting of G Medical Innovations Holdings Ltd. will be virtually held on 15 December 2023, commencing at 10am EST U.S. G Medical Innovations Holdings Ltd. (the “Company”) strongly encourages all shareholders (the “Shareholders”) to vote by directed proxy for the extraordinary general meeting (“Meeting” or “EGM”). Proxy |
|
| November 29, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2023 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Address of principal executive |
|
| October 24, 2023 |
SC 13D/A 1 ea187226-13da1rubinigmed.htm AMENDMENT NO. 1 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1) Under the Securities Exchange Act of 1934 G Medical Innovations Holdings Ltd. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G39462141 (CUSIP Number) Jonathan B. Rubini P.O. Box 2 |
|
| October 10, 2023 |
Exhibit 99.1 EXECUTION COPY SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 29, 2023, between G Medical Innovations Holdings Ltd., a Cayman Islands exempted company (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). W |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2023 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Address of principa |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2023 (Report No. 2) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Ad |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2023 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Address of princi |
|
| August 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2023 (Report No. 5) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Addre |
|
| August 25, 2023 |
Exhibit 99.2 G MEDICAL INNOVATIONS HOLDINGS LTD. (Incorporated in the Cayman Islands with limited liability) (NASDAQ: GMVD) PROXY STATEMENT ANNUAL GENERAL MEETING To Be Held on 12 September 2023 This Proxy Statement is furnished to the members (“Shareholders”) of record at the close of business on 9 August 2023 (the “Record Date”) of G Medical Innovations Holdings Ltd. (“we” or the “Company”) in c |
|
| August 25, 2023 |
Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING The Annual General Meeting of G Medical Innovations Holdings Ltd. will be virtually held on 12 September 2023, commencing at 10:00am EDT US G Medical Innovations Holdings Ltd. (the “Company”) strongly encourages all shareholders (the “Shareholders”) to vote by directed proxy for the annual general meeting (“Meeting” or “AGM”). Proxy Forms for the Meeti |
|
| August 25, 2023 |
Exhibit 99.1 G Medical Innovations Holdings Ltd. Announces its ordinary shares and warrants to be quoted on the over-the-counter pink (OTC) under the trading symbols GMVDF and GMVWF; Company intends to apply to quote its shares and warrants on the OTCQB or OTCQX Rehovot, Israel, August 24th, 2023– G Medical Innovations Holdings Ltd. (OTC: GMVDF) (“G Medical Innovations”), an industry innovator in |
|
| August 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2023 (Report No. 4) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Addre |
|
| August 25, 2023 |
Exhibit 99.3 |
|
| August 25, 2023 |
SC 13D/A 1 ea184069-13da2gevagmed.htm AMENDMENT NO. 2 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2) Under the Securities Exchange Act of 1934 G Medical Innovations Holdings Ltd. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G39462 141 (CUSIP Number) Yacov Geva 5 Oppenheimer St. R |
|
| August 25, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August 2023 (Report No. 6) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Address of princip |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2023 (Report No. 3) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Addre |
|
| August 18, 2023 |
GMVD / G Medical Innovations Holdings Limited / BIGGER CAPITAL FUND L P Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 G Medical Innovations Holdings Ltd. (Name of Issuer) Ordinary Shares, $.0001 par value (Title of Class of Securities) G39462125 (CUSIP Num |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2023 (Report No. 2) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Addre |
|
| August 17, 2023 |
Exhibit 99.1 G Medical Innovations Will Provide Services to Veterans and Military Personnel by Partnering With Resilient Support Services Rehovot, Israel, Aug. 17, 2023 (GLOBE NEWSWIRE) - G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (“G Medical Innovations”), an industry innovator in comprehensive remote patient monitoring solutions, today announced that its wholly-owned subsidiary, G Medica |
|
| August 8, 2023 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* G Medical Innovations Holdings Ltd. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G39462141 (CUSIP Number) July 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2023 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Address of principal |
|
| August 7, 2023 |
Exhibit 99.1 G Medical Innovations’ CEO Issues Update to Shareholders, August 2023 Rehovot, Israel, Aug. 07, 2023 (GLOBE NEWSWIRE) - G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (“G Medical Innovations” or the “Company”), a global leader in next-generation mobile health (mHealth) and digital health, today issued the following update to shareholders from President and CEO Dr. Yacov Geva. Dear |
|
| July 27, 2023 |
As filed with the Securities and Exchange Commission on July 27, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 G MEDICAL INNOVATIONS HOLDINGS LTD. |
|
| July 27, 2023 |
G- Medical Innovations Holdings LTD Exhibit 10.18 G- Medical Innovations Holdings LTD July 3rd, 2023 Management of the board of Directors Dear Sir, As the CEO and major shareholder of G-Medical innovations Holdings LTD, I hereby approve my commitment to finance the Company’s operations for 13 months from this letter up to August 3rd, 2024, provided and as long as, the company cannot be finance externally from any other sources and/ |
|
| July 27, 2023 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) G MEDICAL INNOVATIONS HOLDINGS LTD. |
|
| July 5, 2023 |
As filed with the Securities and Exchange Commission on July 5, 2023 As filed with the Securities and Exchange Commission on July 5, 2023 Registration No. |
|
| July 5, 2023 |
G MEDICAL INNOVATIONS HOLDINGS LTD. 2016 Global Amended and Restated Equity Incentive Plan Exhibit 99.1 G MEDICAL INNOVATIONS HOLDINGS LTD. 2016 Global Amended and Restated Equity Incentive Plan 1. Purpose The purpose of the 2016 Global Equity Incentive Plan is to provide eligible employees, directors, consultants and sub-contractors of the Company and its Affiliates the ability to share in the Company’s future success. Through this Global Equity Incentive Plan, the Company has establis |
|
| July 5, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) G Medical Innovations Holdings Ltd. |
|
| June 1, 2023 |
Exhibit 16.1 June 1, 2023 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the periodic report on Form 6-K for the event that occurred on June 1, 2023, to be filed by our former client, G Medical Innovations Holdings Ltd. we agree with the statements made in that report insofar as they relate to our Firm. Very truly yours, /S/ Ziv Ha |
|
| June 1, 2023 |
6-K 1 ea179550-6kgmedical.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2023 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2023 (Report No. 2) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Address |
|
| May 19, 2023 |
G Medical Innovations Holdings Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification Exhibit 99.1 G Medical Innovations Holdings Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification Rehovot, Israel, May 19, 2023 (GLOBE NEWSWIRE) – G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company”), a telehealth, medical device, and remote patient monitoring company, announced today that on May 15, 2023 it received a written notice (the “Notice”) from Nasdaq Stock Market |
|
| May 16, 2023 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2022 (the “Report”) by G Medical Innovations Holdings Ltd. (the “company”), the undersigned, as the Chief Executive Officer of the company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully com |
|
| May 16, 2023 |
G- Medical Innovations Holdings LTD Exhibit 4.18 G- Medical Innovations Holdings LTD May 15th, 2023 Management of the board of Directors Dear Sir, As the CEO of G-Medical innovations Holdings LTD, I hereby approve my commitment to finance the Company’s operations for 12 months from this letter up to May 30th ,2024, provided and as long as, the company cannot be finance externally from any other sources and/ or until a sum of $10 mil |
|
| May 16, 2023 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Yacov Geva, certify that: 1. I have reviewed this annual report on Form 20–F of G Medical Innovations Holdings Ltd. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the c |
|
| May 16, 2023 |
Exhibit 99.1 G Medical Innovations Holdings Ltd. Announces Receipt of Nasdaq Hearings Panel’s Decision to Grant Exception for Continued Listing Rehovot, Israel, May 15, 2023 (GLOBE NEWSWIRE) - G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company”) announced today that, on May 11, 2023, the Company received notice from the Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Na |
|
| May 16, 2023 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Igor Bluvstein, certify that: 1. I have reviewed this annual report on Form 20–F of G Medical Innovations Holdings Ltd. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t |
|
| May 16, 2023 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2022 (the “Report”) by G Medical Innovations Holdings Ltd. (the “company”), the undersigned, as the Chief Financial Officer of the company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully com |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Commission File No. |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2023 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Address of principal ex |
|
| May 16, 2023 |
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT Exhibit 15.1 INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT G Medical Innovations Holdings Ltd. Rehovot 7670105, Israel We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-266090) and Form S-8 (No. 333-266063) of G Medical Innovations Holdings Ltd. of our report dated May 15, 2023, relating to the consolidated financial statements, which |
|
| May 16, 2023 |
Exhibit 2.2 Description of Securities The following are summaries of material provisions of our Amended and Restated Memorandum and Articles of Association adopted by special resolution passed on February 16, 2023 (or the Amended and Restated Memorandum and Articles of Association) and the Companies Act (as amended) of the Cayman Islands (or the Cayman Islands Companies Act) insofar as they relate |
|
| May 2, 2023 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: . . . . . 3235-0058 Washington, D.C. 20549 Expires: April 30, 2025 Estimated average burden hours FORM 12b-25 per response. . . . . . . . 2.50 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-39674 CUSIP NUMBER G39462141 (Check one): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Per |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2023 (Report No. 2) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Addres |
|
| April 18, 2023 |
Exhibit 99.1 G MEDICAL UPDATES ON PATIENT ENROLLMENT GROWTH FOR ITS HOME MONITORING SERVICES OF 194% FROM JANUARY THROUGH APRIL 2023, AS COMPARED TO THE SAME PERIOD IN 2022 Rehovot, Israel, April 18, 2023 (GLOBE NEWSWIRE) - G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company” or “G Medical”), a global leader in next-generation mobile health (mHealth) and digital health, is excited to |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1) Under the Securities Exchange Act of 1934 G Medical Innovations Holdings Ltd. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G39462 141 (CUSIP Number) Yacov Geva 5 Oppenheimer St. Rehovot, Israel 7670105 (Name, Address and Telephone Number of Person A |
|
| April 6, 2023 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated April 3, 2023 with respect to the ordinary shares of G Medical Innovations Holdings Ltd., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) und |
|
| April 6, 2023 |
GMVD / G Medical Innovations Holdings Limited / BIGGER CAPITAL FUND L P Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 G Medical Innovations Holdings Ltd. (Name of Issuer) Ordinary Shares, $.0001 par value (Title of Class of Securities) G39462125 (CUSIP Numb |
|
| April 4, 2023 |
G Medical Innovations Holdings Ltd. Announces Closing of Public Offering Exhibit 99.2 G Medical Innovations Holdings Ltd. Announces Closing of Public Offering Rehovot, Israel, April 04, 2023 (GLOBE NEWSWIRE) - G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company”), a global leader in next-generation mobile health (mHealth) and digital health, today announced the closing of its public offering of 12,000,000 ordinary shares (or pre-funded warrants (“Pre-Funde |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2023 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Address of principal |
|
| April 4, 2023 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-269496 5,470,000 Ordinary Shares 6,530,000 Pre-Funded Warrants to Purchase Ordinary Shares G Medical Innovations Holdings Ltd. This is a firm commitment offering of 5,470,000 ordinary shares, par value $0.0001 per share (the “Ordinary Shares”). We are also offering to each purchaser whose purchase of Ordinary Shares in this offering would other |
|
| April 4, 2023 |
G Medical Innovations Holdings Ltd. Announces Pricing of Public Offering Exhibit 99.1 G Medical Innovations Holdings Ltd. Announces Pricing of Public Offering Rehovot, Israel, March 31, 2023 (GLOBE NEWSWIRE) - G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company”), a global leader in next-generation mobile health (mHealth) and digital health, today announced the pricing of an underwritten public offering of 12,000,000 ordinary shares (or pre-funded warrants |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2023 (Report No. 3) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Addres |
|
| March 29, 2023 |
Exhibit 99.1 G MEDICAL INNOVATIONS AND ADVENTHEALTH IN JOINT COLLABORATION TO PROVIDE INNOVATIVE REMOTE PATIENT MONITORING SOLUTIONS FOR ADVENTHEALTH PATIENTS IN CENTRAL FLORIDA Rehovot, Israel, March 29, 2023 (GLOBE NEWSWIRE) – G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company” or “G Medical Innovations”), a global leader in next-generation mobile health (mHealth) and digital healt |
|
| March 27, 2023 |
ThinkEquity LLC 17 State Street, 41st Fl New York, NY 10004 ThinkEquity LLC 17 State Street, 41st Fl New York, NY 10004 March 27, 2023 VIA EDGAR U. |
|
| March 27, 2023 |
G Medical Innovations Holdings Ltd. 5 Oppenheimer St. Rehovot, Israel 7670105 G Medical Innovations Holdings Ltd. 5 Oppenheimer St. Rehovot, Israel 7670105 March 27, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: G Medical Innovations Holdings Ltd. (CIK: 0001760764) Registration Statement No. 333-269496 on Form F-1 (the “Registration Statement”) Ladies and Gentlemen: G Medical Innovations Holding |
|
| March 27, 2023 |
As filed with the Securities and Exchange Commission on March 27, 2023 As filed with the Securities and Exchange Commission on March 27, 2023 Registration No. |
|
| March 27, 2023 |
6-K 1 ea175799-6kgmedical.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2023 (Report No. 2) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name |
|
| March 27, 2023 |
MEDICAL March 2023 INVESTOR PRESENTATION Nasdaq: GMVD Free Writing Prospectus Dated March 27, 2023 Filed pursuant to Rule 433 Relating to Preliminary Prospectus Dated March 24, 2023 Registration Statement on Form F - 1 (No. |
|
| March 27, 2023 |
Exhibit 99.1 G MEDICAL INNOVATIONS AND MICARE PATH ANNOUNCE JOINT COLLABORATION TO PROVIDE INNOVATIVE REMOTE PATIENT MONITORING SOLUTIONS GLOBALLY Rehovot, Israel, March 27, 2023 (GLOBE NEWSWIRE) - G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company” or “G Medical Innovations”), a global leader in next-generation mobile health (mHealth) and digital health, and MiCare Path, a leader in |
|
| March 24, 2023 |
Exhibit 10.16 G- Medical Innovations Holdings LTD March 24th, 2023 Management of the board of Directors Dear Sir, As the CEO and controlling shareholder of G-Medical innovations Holdings LTD, I hereby approve my extension commitment to finance the Company's operations for 12 months from this letter up to April 30th, 2024, provided and as long as, I am a controlling shareholder and / or the company |
|
| March 24, 2023 |
As filed with the Securities and Exchange Commission on March 24, 2023 As filed with the Securities and Exchange Commission on March 24, 2023 Registration No. |
|
| March 24, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) G MEDICAL INNOVATIONS HOLDINGS LTD. |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2023 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Address of principal |
|
| March 23, 2023 |
Exhibit 99.1 THE COMPANIES ACT (AS REVISED) OF THE CAYMAN ISLANDS EXEMPTED COMPANY LIMITED BY SHARES MEMORANDUM AND ARTICLES OF ASSOCIATION OF G MEDICAL INNOVATIONS HOLDINGS LTD. (ADOPTED BY SPECIAL RESOLUTION PASSED ON 16 FEBRUARY 2023) (EFFECTIVE ON THE ‘EFFECTIVE DATE’ AS DEFINED IN ACCORDANCE WITH THE SPECIAL RESOLUTION PASSED ON 16 FEBRUARY 2023) 1 Filed: 20-Feb-2023 11:06 EST www.verify.gov. |
|
| February 28, 2023 |
Exhibit 4.2 PRE-FUNDED WARRANT AGENT AGREEMENT This Warrant Agent Agreement made as of , 2023, is between G Medical Innovations Holdings Limited, a Cayman Islands corporation, with offices at 5 Oppenheimer St. Rehovot 7670105, Israel (the “Company”), and VStock Transfer, LLC, with offices at 18 Lafayette Place, Woodmere, New York (the “Warrant Agent”). WHEREAS, the Company has determined to issue |
|
| February 28, 2023 |
As filed with the Securities and Exchange Commission on February 28, 2023 As filed with the Securities and Exchange Commission on February 28, 2023 Registration No. |
|
| February 28, 2023 |
Exhibit 4.3 THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE EFFECTIVE DATE (DEFIN |
|
| February 28, 2023 |
Form of Underwriting Agreement Exhibit 1.1 UNDERWRITING AGREEMENT between G Medical Innovations Holdings Ltd. and THINKEQUITY LLC as Representative of the Several Underwriters UNDERWRITING AGREEMENT New York, New York [●], 2023 ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 41st Fl New York, NY 10004 Ladies and Gentlemen: The undersigned, G Medical Innovations |
|
| February 28, 2023 |
Exhibit 10.15 G- Medical Innovations Holdings LTD January 30th, 2023 Management of the board of Directors Dear Sir, As the CEO and controlling shareholder of G-Medical innovations Holdings LTD, I hereby approve my extension commitment to finance the Company's operations from 30-11-2023 up to 28-2-2024, provided and as long as, I am a controlling shareholder and / or the company cannot be finance e |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2023 (Report No. 4) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Add |
|
| February 28, 2023 |
Exhibit 4.1 PRE-FUNDED Ordinary shareS PURCHASE WARRANT G Medical Innovations Holdings Ltd. Warrant Shares: [●] Issue Date: , 2023 THIS PRE-FUNDED ORDINARY SHARES PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after t |
|
| February 28, 2023 |
MEDICAL February 2023 INVESTOR PRESENTATION Nasdaq: GMVD Free Writing Prospectus Dated February 28 , 2023 Filed pursuant to Rule 433 Relating to Preliminary Prospectus Dated February 28 , 2023 Registration Statement on Form F - 1 (No . |
|
| February 21, 2023 |
Exhibit 99.1 G Medical Innovations Holdings Ltd Announces Nasdaq Staff Listing Determination; Plans to Request Hearing Rehovot, Israel, Feb. 17, 2023 (GLOBE NEWSWIRE) - G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company”) announced today that on February 16, 2023, the Company received notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nas |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2023 (Report No. 3) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Add |
|
| February 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2023 (Report No. 2) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Add |
|
| February 13, 2023 |
G Medical Innovations announces receipt of patent from USPTO for vital signs sensors Exhibit 99.1 G Medical Innovations announces receipt of patent from USPTO for vital signs sensors Rehovot, Israel, Feb. 13, 2023 (GLOBE NEWSWIRE) – G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company” or “G Medical Innovations”) today announced that the patent US 11,571,167 “Method and System For Vital Signs Monitoring With Earpiece” has been issued as of February 7, 2023. Two weeks a |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2023 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Address of princip |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 G Medical Innovations Holdings Ltd. (Name of Issuer) Ordinary Shares, par value $3.15 per share (Title of Class of Securities) G39462125 (CUSIP Number) Jonathan B. Rubini P.O. Box 202845 Anchorage, Alaska 99520-2845 (Name, Address and Telephone Number of Person Authorized |
|
| February 1, 2023 |
Exhibit 21.1 LIST OF SUBSIDIARIES Entity Name Jurisdiction of Incorporation G Medical Innovations Ltd. Israel G Medical Innovations Asia Ltd. Hong Kong G Medical Innovations UK Ltd. United Kingdom Guangzhou Yimei Innovative Medical Science and Technology Co., Ltd. China G Medical Innovations MK Ltd. Macedonia G Medical Innovations USA Inc. Delaware G Medical Diagnostic Services, Inc. (Formerly Car |
|
| February 1, 2023 |
Power of Attorney (included on the signature page of the Registration Statement). As filed with the Securities and Exchange Commission on February 1, 2023 Registration No. |
|
| February 1, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) G MEDICAL INNOVATIONS HOLDINGS LTD. |
|
| January 31, 2023 |
SC 13G 1 GMedicalInnovationsHold.htm FILING G MEDICAL INNOVATIONS HOLDINGS LTD. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* G Medical Innovations Holdings Ltd. (Name of Issuer) Ordinary Shares, par value $0.09 per share (Title of Class of Securities) G39462125 (CUSIP Number) December 30, 2022 (Date |
|
| January 30, 2023 |
GMVD / G Medical Innovations Holdings Ltd. / Geva Yacov - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 G Medical Innovations Holdings Ltd. (Name of Issuer) Ordinary Shares, par value $3.15 per share (Title of Class of Securities) G39462125 (CUSIP Number) Yacov Geva 5 Oppenheimer St. Rehovot, Israel 7670105 (Name, Address and Telephone Number of Person Authorized to Receive |
|
| January 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2022 (Report No. 3) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Addr |
|
| January 30, 2023 |
Exhibit 99.1 G Medical Innovations announces receiving notice of patent issuance from the USPTO for vital signs sensors Rehovot, Israel, Jan. 30, 2023 (GLOBE NEWSWIRE) – G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company” or “G Medical Innovations”) today announced that it has received a patent issue notification from the United States Patent and Trademark Office (“USPTO”) for its mo |
|
| January 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of: January 2023 (Report No. 2) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Add |
|
| January 24, 2023 |
NOTICE OF EXTRAORDINARY GENERAL MEETING EX-99.1 2 f6k0123ex99-1gmedicalinno.htm NOTICE AND PROXY STATEMENT FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 9, 2023. Exhibit 99.1 NOTICE OF EXTRAORDINARY GENERAL MEETING The Extraordinary General Meeting of G Medical Innovations Holdings Ltd. will be virtually held on 9 February 2023, commencing at 5:00pm (Israel time) G Medical Innovations Holdings Ltd. (the “C |
|
| January 24, 2023 |
Exhibit 99.3 Your Vote Counts! G MEDICAL INNOVATIONS HOLDINGS LTD. 2023 Extraordinary General Meeting Vote by February 7, 2023 11:59pm Eastern Time G MEDICAL INNOVATIONS HOLDINGS LTD. 5 OPPENHEIMER STREET REHOVOT ISRAEL D95889-S61083 You invested in G MEDICAL INNOVATIONS HOLDINGS LTD. and it’s time to vote! You have the right to vote on proposals being presented at the Extraordinary General Meetin |
|
| January 24, 2023 |
Exhibit 99.2 G MEDICAL INNOVATIONS HOLDINGS LTD. 5 OPPENHEIMER STREET REHOVOT ISRAEL SCAN TO VIEW MATERIALS & VOTE VOTE BY INTERNET - www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time on February 7, 2023. Follow the instructions to obtain your records and to create an elec |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2023 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Address of principa |
|
| December 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2022 (Report No. 4) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 7 Vanderbilt Irvine, CA 92618 (Address of prin |
|
| December 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2022 (Report No. 3) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 7 Vanderbilt Irvine, CA 92618 (Address of prin |
|
| December 16, 2022 |
Exhibit 99.3 |
|
| December 16, 2022 |
Exhibit 99.2 |
|
| December 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of: December 2022 (Report No. 2) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 7 Vanderbilt Irvine CA 92618 (Address of prin |
|
| December 16, 2022 |
NOTICE OF EXTRAORDINARY GENERAL MEETING Exhibit 99.1 NOTICE OF EXTRAORDINARY GENERAL MEETING The Extraordinary General Meeting of G Medical Innovations Holdings Ltd. will be virtually held on 23 December 2022, commencing at 5:00pm (Israel time) G Medical Innovations Holdings Ltd. (the “Company”) strongly encourages all shareholders (the “Shareholders”) to vote by directed proxy for the extraordinary general meeting (the “Meeting”). Prox |
|
| December 5, 2022 |
Exhibit 99.1 G Medical Innovations to announce receiving of 2 (two) granted patents from the USPTO for its Prizma care and other physiological sensors developed by the company. Irvine, California, Dec. 05, 2022 (GLOBE NEWSWIRE) ? G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) (the ?Company? or ?G Medical Innovations?) today announced that it received 2 (Two) granted patents from the United Sta |
|
| December 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2022 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 7 Vanderbilt Irvine CA 92618 (Address of principal executive |
|
| November 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2022 (Report No. 2) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 7 Vanderbilt Irvine CA 92618 (Address of pr |
|
| November 22, 2022 |
EX-99.1 2 ea169150ex99-1gmedical.htm PRESS RELEASE TITLED: "G MEDICAL INNOVATIONS HOLDINGS LTD. (NASDAQ: GMVD) ANNOUNCES RECEIPT OF NOTICE OF DEFICIENCY WITH NASDAQ CONTINUED LISTING REQUIREMENTS" Exhibit 99.1 G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements Irvine, California, Nov. 22, 2022 (GLOBE NEWSWIRE) - G |
|
| November 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2022 (Report No. 4) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 7 Vanderbilt Irvine CA 92618 (Address of princ |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2022 (Report No. 3) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 7 Vanderbilt Irvine CA 92618 (Address of princ |
|
| November 18, 2022 |
G- Medical Innovations Holdings LTD Exhibit 99.4 G- Medical Innovations Holdings LTD October 6th, 2022 Management of the board of Directors Dear Sir, As the CEO and controlling shareholder of G-Medical innovations Holdings LTD, I hereby approve my commitment to finance the Company’s operations from this letter up to 30-11-2023, provided and as long as, I am a controlling shareholder and/or the company cannot be finance externally fr |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2022 (Report No. 2) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 7 Vanderbilt Irvine CA 92618 (Address of princ |
|
| November 18, 2022 |
Exhibit 99.1 THE COMPANIES ACT (AS REVISED) OF THE CAYMAN ISLANDS EXEMPTED COMPANY LIMITED BY SHARES MEMORANDUM AND ARTICLES OF ASSOCIATION OF G MEDICAL INNOVATIONS HOLDINGS LTD. (adopted by Special Resolution passed on NOVEMBER 15, 2022) THE COMPANIES ACT (AS REVISED) OF THE CAYMAN ISLANDS EXEMPTED COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF G MEDICAL INNOVATIONS HOLDINGS LTD. (adopted |
|
| November 18, 2022 |
G Medical Innovations Holdings Ltd. Exhibit 99.1 G Medical Innovations Holdings Ltd. Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2022 Table of Contents Unaudited Interim Condensed Consolidated Financial Statements: Page Unaudited Interim Condensed Consolidated Statements of Financial Position 2 Unaudited Interim Condensed Consolidated Statements of Loss and Other Comprehensive Loss 3 Unaudited Interi |
|
| November 18, 2022 |
G Medical Innovations Announces First Half 2022 Financial Results and Provides Business Update Exhibit 99.3 G Medical Innovations Announces First Half 2022 Financial Results and Provides Business Update Irvine, CA, Nov. 18, 2022 (GLOBE NEWSWIRE) - G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (“G Medical” or the “Company”), an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms, toda |
|
| November 18, 2022 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read in conjuncti |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of: November 2022 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 7 Vanderbilt Irvine CA 92618 (Address of principal executive |
|
| November 9, 2022 |
Proxy Card for the Extraordinary General Meeting of Shareholders to be held on November 15, 2022. Exhibit 99.2 |
|
| November 9, 2022 |
Exhibit 99.1 NOTICE OF EXTRAORDINARY GENERAL MEETING The Extraordinary General Meeting of G Medical Innovations Holdings Ltd. will be at the physical location of the Chairman and virtually held on November 15, 2022, commencing at 5:00pm (Israel time) G Medical Innovations Holdings Ltd. (the “Company”) strongly encourages all shareholders (the “Shareholders”) to vote by directed proxy for the extra |
|
| November 1, 2022 |
Proxy Card for the Extraordinary General Meeting of Shareholders to be held on November 15, 2022. Exhibit 99.2 |
|
| November 1, 2022 |
Exhibit 99.3 ONLINE VOTING To vote your proxy electronically, please go to www.vstocktransfer.com/proxy You must reference your 12-digit control number listed below. Vstock Transfer, LLC 18 Lafayette Place CONTROL # Woodmere, New York 11598 REQUESTING A PAPER OR ELECTRONIC COPY OF THE PROXY MATERIALS * SPECIMEN * 1 MAIN STREET ANYWHERE PA 99999-9999 Have this notice available when you request a pa |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of: October 2022 (Report No. 3) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 7 Vanderbilt Irvine CA 92618 (Address of princ |
|
| November 1, 2022 |
Exhibit 99.1 NOTICE OF EXTRAORDINARY GENERAL MEETING The Extraordinary General Meeting of G Medical Innovations Holdings Ltd. will be at the physical location of the Chairman and virtually held on November 15, 2022, commencing at 5:00pm (Israel time) G Medical Innovations Holdings Ltd. (the “Company”) strongly encourages all shareholders (the “Shareholders”) to vote by directed proxy for the extra |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2022 (Report No. 2) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’s name into English) 7 Vanderbilt Irvine CA 92618 (Address of princi |
|
| October 27, 2022 |
SECOND AMENDED AND RESTATED 10% CONVERTIBLE DEBENTURE DUE OCTOBER 1, 2022 Exhibit 99.2 Execution Version NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO |
|
| October 27, 2022 |
G- Medical Innovations Holdings LTD Exhibit 99.4 G- Medical Innovations Holdings LTD October 6th, 2022 Management of the board of Directors Dear Sir, As the CEO and controlling shareholder of G-Medical innovations Holdings LTD, I hereby approve my commitment to finance the Company's operations for 12 months from this letter [ Ends of October 15th 2023 ] provided and as long as, I am a controlling shareholder and / or the company can |
|
| October 27, 2022 |
Exhibit 99.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 20, 2022, between G Medical Innovations Holdings Ltd., a Cayman Islands exempted company (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). |
|
| October 27, 2022 |
WARRANT TO PURCHASE ORDINARY SHARES G Medical Innovations HOLDINGS LTD. Exhibit 99.3 Execution Version NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO A |
|
| October 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2022 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 7 Vanderbilt Irvine CA 92618 (Address of principal executive o |
|
| October 6, 2022 |
Perimenopause Estradiol, FSH, Progesterone Exhibit 99.1 G Medical Innovations is introducing a Monkeypox consumer home health test kit, along with 30 new direct to consumer home health testing kits with 24 to 48 hours results October 6, 2022 IRVINE, California, Oct. 06, 2022 (GLOBE NEWSWIRE) - G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) (the ?Company? or ?G Medical Innovations?) today announced that its wholly owned subsidiary, G. M |
|
| September 19, 2022 |
G Medical Innovations Holdings Ltd. Up to $3,000,000 Ordinary Shares Filed pursuant to Rule 424(b)(5) Registration No. 333-266090 PROSPECTUS SUPPLEMENT (To prospectus dated August 8, 2022) G Medical Innovations Holdings Ltd. Up to $3,000,000 Ordinary Shares We have entered into a sales agreement, or the Sales Agreement with A.G.P./Alliance Global Partners (?A.G.P.?), dated September 16, 2022, relating to the sale of our ordinary shares, par value $0.09 per share (? |
|
| September 19, 2022 |
Exhibit 10.1 Execution Version G MEDICAL INNOVATIONS HOLDINGS LTD. ORDINARY SHARES SALES AGREEMENT September 16, 2022 A.G.P./Alliance Global Partners 590 Madison Avenue New York, NY 10022 Ladies and Gentlemen: G Medical Innovations Holdings Ltd., a Cayman Islands exempted company (the ?Company?), confirms its agreement (this ?Agreement?) with A.G.P./Alliance Global Partners (the ?Sales Agent?), as |
|
| September 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2022 (Report No. 2) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 7 Vanderbilt Irvine CA 92618 (Address of prin |
|
| September 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2022 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 7 Vanderbilt Irvine CA 92618 (Address of principal executive |
|
| August 4, 2022 |
G Medical Innovations Holdings Ltd. 5 Oppenheimer St. Rehovot, Israel 7670105 G Medical Innovations Holdings Ltd. 5 Oppenheimer St. Rehovot, Israel 7670105 August 4th, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: G Medical Innovations Holdings Ltd. (CIK: 0001760764) Registration Statement No. 333-266090 on Form F-3 (the ?Registration Statement?) Request for Acceleration of Effective Date Ladies |
|
| July 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2022 (Report No. 4) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 7 Vanderbilt Irvine CA 92618 (Address of principal |
|
| July 18, 2022 |
Exhibit 99.2 AMENDMENT AGREEMENT July 18, 2022 1. Securities Purchase Agreement. Reference is made to that certain Securities Purchase Agreement (the ?SPA?), dated April 18, 2022, by and between G Medical Innovations Holdings Ltd., a company organized in the Cayman Islands (the ?Company?) and Armistice Capital Master Fund Ltd. (the ?Purchaser?), which sets forth the terms and agreements governing |
|
| July 18, 2022 |
ORDINARY SHARE PURCHASE WARRANT G MEDICAL INNOVATIONS HOLDINGS LTD. Exhibit 99.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| July 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2022 (Report No. 3) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 7 Vanderbilt Irvine CA 92618 (Address of principal |
|
| July 18, 2022 |
G MEDICAL INNOVATIONS HOLDINGS LTD. Exhibit 99.1 G MEDICAL INNOVATIONS HOLDINGS LTD. July 18, 2022 Holder of Ordinary Share Purchase Warrant Re: Inducement Offer to Exercise Ordinary Share Purchase Warrants Dear Holder: G Medical Innovations Holdings Ltd. (the ?Company?) is pleased to offer to you the opportunity to exercise all of the Ordinary Share Purchase Warrants of the Company set forth on the signature page hereto (the ?Exist |
|
| July 13, 2022 |
As filed with the Securities and Exchange Commission on July 13, 2022. As filed with the Securities and Exchange Commission on July 13, 2022. Registration No. 333-262724 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Post-Effective Amendment No. 1 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 G MEDICAL INNOVATIONS HOLDINGS LTD. (Exact name of registrant as specified in its charter) Cayman Islands 3841 Not Applicable (State |
|
| July 13, 2022 |
Exhibit 99.1 Media Inquiries Christine Haas, Haas Communications [email protected] (512) 751-1592 G Medical Innovations is introducing affordable, new direct to consumer home health testing kits with quick results ? The first 7 new health testing kits covering Food sensitivity (96 and 208 types of food), indoor/outdoor allergies, Thyroid functioning, testosterone levels, HbA1C and HPV te |
|
| July 13, 2022 |
As filed with the Securities and Exchange Commission on July 13, 2022. As filed with the Securities and Exchange Commission on July 13, 2022. Registration No. 333-262422 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Post-Effective Amendment No. 1 to Amendment No. 1 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 G MEDICAL INNOVATIONS HOLDINGS LTD. (Exact name of registrant as specified in its charter) Cayman Islands 3841 No |
|
| July 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2022 (Report No. 2) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 7 Vanderbilt Irvine CA 92618 (Address of principal |
|
| July 11, 2022 |
Calculation of Filing Fee Tables. Exhibit 107 Calculation of Filing Fee Tables FORM F-3 (Form Type) G MEDICAL INNOVATIONS HOLDINGS LTD. |
|
| July 11, 2022 |
As filed with the Securities and Exchange Commission on July 11, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 G MEDICAL INNOVATIONS HOLDINGS LTD. (Exact name of registrant as specified in its charter) Cayman Islands Not Applicable (State or other jurisdiction of (I.R.S. Employer in |
|
| July 11, 2022 |
Exhibit 10.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS |
|
| July 8, 2022 |
As filed with the Securities and Exchange Commission on July 8, 2022 Registration No. |
|
| July 8, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) G Medical Innovations Holdings Ltd. |
|
| July 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2022 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 7 Vanderbilt Irvine CA 92618 (Address of principal executive offi |
|
| June 17, 2022 |
Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING The Annual General Meeting of G Medical Innovations Holdings Ltd. will be at 5 Oppenheimer St. Rehovot 7670105, Israel held on July 20, 2022, commencing at 5:00 p.m. (Israel time) G Medical Innovations Holdings Ltd (the ?Company?) advises Shareholders that the annual general meeting (?Meeting?) will be held in compliance with any restrictions on public |
|
| June 17, 2022 |
Exhibit 99.3 VOTE ON INTERNET Go to http://www.vstocktransfer.com/proxy Click on Proxy Voter Login and log-on using the below control number. Voting will be open until 11:59 pm EST on July 19, 2022. CONTROL # VOTE BY EMAIL Mark, sign and date your proxy card and return it to [email protected] VOTE BY MAIL * SPECIMEN * 1 MAIN STREET Mark, sign and date your proxy card and return it in the env |
|
| June 17, 2022 |
Exhibit 99.1 G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) Announces Receipt of Nasdaq Minimum Bid Price Notification Irvine, California, June 17, 2022 (GLOBE NEWSWIRE) - G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the ?Company?), a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare |
|
| June 17, 2022 |
Exhibit 99.2 G MEDICAL INNOVATIONS HOLDINGS LTD. (Incorporated in the Cayman Islands with limited liability) (NASDAQ: GMVD) PROXY STATEMENT ANNUAL GENERAL MEETING To Be Held on July 20, 2022 This Proxy Statement is furnished to the members (?Shareholders?) of record at the close of business on June 9, 2022 (the ?Record Date?) of G Medical Innovations Holdings Ltd. (?we? or the ?Company?) in connec |
|
| June 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2022 (Report No. 3) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 7 Vanderbilt Irvine CA 92618 (Address of principal |
|
| June 17, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June 2022 (Report No. 2) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 7 Vanderbilt Irvine CA 92618 (Address of principal executive of |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2022 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Address of principal e |
|
| May 26, 2022 |
G Medical Innovations Holdings Ltd. 5 Oppenheimer St. Rehovot, Israel 7670105 G Medical Innovations Holdings Ltd. 5 Oppenheimer St. Rehovot, Israel 7670105 May 26, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: G Medical Innovations Holdings Ltd. (CIK: 0001760764) Registration Statement No. 333-265089 on Form F-1 (the ?Registration Statement?) Request for Acceleration of Effective Date Ladies and |
|
| May 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2022 (Report No. 2) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Address |
|
| May 20, 2022 |
G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) Announces Share Repurchase Program Exhibit 99.1 G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) Announces Share Repurchase Program Irvine, California, May 20, 2022, G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) (the ?Company?) today announced that its board of directors has authorized a share repurchase program to acquire up to $1 million of the Company's ordinary shares (the ?Repurchase Plan?). The Company may purchase ord |
|
| May 19, 2022 |
EX-21.1 3 ea160230ex21-1gmedicalinno.htm LIST OF SUBSIDIARIES Exhibit 21.1 LIST OF SUBSIDIARIES Entity Name Jurisdiction of Incorporation G Medical Innovations Ltd. Israel G Medical Innovations Asia Ltd. Hong Kong G Medical Innovations UK Ltd. United Kingdom Guangzhou Yimei Innovative Medical Science and Technology Co., Ltd. China G Medical Innovations MK Ltd. Macedonia G Medical Innovations USA I |
|
| May 19, 2022 |
Power of Attorney (included on the signature page of the Registration Statement). As filed with the Securities and Exchange Commission on May 19, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 G MEDICAL INNOVATIONS HOLDINGS LTD. (Exact name of registrant as specified in its charter) Cayman Islands 3841 Not Applicable (State or other jurisdiction of incorporation o |
|
| May 19, 2022 |
Calculation of Filing Fee Tables. Exhibit 107 Calculation of Filing Fee Tables FORM F-1 (Form Type) G MEDICAL INNOVATIONS HOLDINGS LTD. |
|
| May 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2022 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Address of principal ex |
|
| May 18, 2022 |
G Medical Innovations (NASDAQ: GMVD) Provides Update Regarding its Forecast for Q1 2022 Revenues Exhibit 99.1 G Medical Innovations (NASDAQ: GMVD) Provides Update Regarding its Forecast for Q1 2022 Revenues Irvine, CA ? May 18, 2022 ? G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) (the ?Company?), today announced that it will not meet its forecast of $30 million in revenues for the first quarter of 2022. While the Company is still working on finalizing most of the revenue figures for the |
|
| April 29, 2022 |
EX-2.1 2 f20f2021ex2-1gmedical.htm DESCRIPTION OF SECURITIES Exhibit 2.1 Description of Securities The following are summaries of material provisions of our Amended and Restated Memorandum and Articles of Association and the Cayman Islands Companies Law insofar as they relate to the material terms of our share capital. This discussion does not purport to be complete and is qualified in its entiret |
|
| April 29, 2022 |
Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350. Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2021 (the “Report”) by G Medical Innovations Holdings Ltd. (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully com |
|
| April 29, 2022 |
Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350. Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2021 (the “Report”) by G Medical Innovations Holdings Ltd. (the “Company”), the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully com |
|
| April 29, 2022 |
Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Kobi Ben-Efraim, certify that: 1. I have reviewed this annual report on Form 20–F of G Medical Innovations Holdings Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstance |
|
| April 29, 2022 |
Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Yacov Geva, certify that: 1. I have reviewed this annual report on Form 20–F of G Medical Innovations Holdings Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances und |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Commission File No. |
|
| April 21, 2022 |
G Medical Innovations Holdings Ltd Announces Closing of $8 Million Private Placement EX-99.1 2 ea158689ex99-1gmedical.htm PRESS RELEASE TITLED "G MEDICAL INNOVATIONS HOLDINGS LTD ANNOUNCES CLOSING OF $8 MILLION PRIVATE PLACEMENT" Exhibit 99.1 G Medical Innovations Holdings Ltd Announces Closing of $8 Million Private Placement TEL AVIV and NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) – G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the “Company”), a telehealth, medical device, and |
|
| April 21, 2022 |
ORDINARY SHARE PURCHASE WARRANT G MEDICAL INNOVATIONS HOLDINGS LTD. Exhibit 99.3 [Execution Version] NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO |
|
| April 21, 2022 |
AMENDMENT NO. 1 TO ORDINARY SHARE PURCHASE WARRANT Exhibit 99.5 AMENDMENT NO. 1 TO ORDINARY SHARE PURCHASE WARRANT This AMENDMENT NO. 1 TO ORDINARY SHARE PURCHASE WARRANT (this ?Amendment?) is effective as of April 20, 2022 by and between G Medical Innovations Holdings Ltd., a Cayman Islands exempted company (the ?Company?) and the holder of certain Warrants (as herein defined) (the ?Holder?). Each of the Company and the Holder shall be referred t |
|
| April 21, 2022 |
Exhibit 99.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of April 20, 2022, between G Medical Innovations Holdings Ltd., a Cayman Islands exempted company (the ?Company?), and each purchaser identified on the signature page hereto (including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the ter |
|
| April 21, 2022 |
AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT EX-99.4 5 ea158689ex99-4gmedical.htm AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT Exhibit 99.4 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This Amended and Restated Registration Rights Agreement (this “Agreement”) is made and entered into as of April 20, 2022, between G Medical Innovations Holdings Ltd., a Cayman Islands exempted company (the “Company”), and each of the several purcha |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2022 (Report No. 2) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Addres |
|
| April 18, 2022 |
ORDINARY SHARE PURCHASE WARRANT G MEDICAL INNOVATIONS HOLDINGS LTD. Exhibit 99.6 [Execution Version] NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO |
|
| April 18, 2022 |
Exhibit 99.3 [Execution Version] REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of April 18, 2022, between G Medical Innovations Holdings Ltd., a Cayman Islands exempted company (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement |
|
| April 18, 2022 |
PRE-FUNDED PURCHASE WARRANT G MEDICAL INNOVATIONS HOLDINGS LTD. EX-99.5 6 ea158539ex99-5gmedical.htm FORM OF PRE-FUNDED WARRANT Exhibit 99.5 [Execution Version] NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), |
|
| April 18, 2022 |
[The remainder of this page has been intentionally left blank.] Exhibit 99.4 [Execution Version] April 18, 2022 G Medical Innovations Ltd. 5 Oppenheimer St. Rehovot 7670105 Israel Attention: Dr. Yacov Geva Dear Dr. Geva: This letter (the ?Agreement?) constitutes the agreement between A.G.P./Alliance Global Partners (the ?Placement Agent?) and G Medical Innovations Holdings Ltd., a Cayman Islands exempted company (the ?Company?), that the Placement Agent shall |
|
| April 18, 2022 |
EX-99.2 3 ea158539ex99-2gmedical.htm SECURITIES PURCHASE AGREEMENT Exhibit 99.2 [Execution Version] SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 18, 2022, between G Medical Innovations Holdings Ltd., a Cayman Islands exempted company (the “Company”), and each purchaser identified on the signature page hereto (including its successors and |
|
| April 18, 2022 |
(Correction) G Medical Innovations Holdings Ltd Announces $7.5 Million Private Placement EX-99.1 2 ea158539ex99-1gmedical.htm PRESS RELEASE ISSUED BY G MEDICAL INNOVATION HOLDINGS LTD. ON APRIL 182022, TITLED "G MEDICAL INNOVATIONS HOLDINGS LTD ANNOUNCES $7.5 MILLION PRIVATE PLACEMENT." Exhibit 99.1 (Correction) G Medical Innovations Holdings Ltd Announces $7.5 Million Private Placement TEL AVIV and NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) - G Medical Innovations Holdings Ltd. (NASDA |
|
| April 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2022 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Address of principal |
|
| April 18, 2022 |
AMENDMENT NO. 1 TO ORDINARY SHARE PURCHASE WARRANT Exhibit 99.8 AMENDMENT NO. 1 TO ORDINARY SHARE PURCHASE WARRANT This AMENDMENT NO. 1 TO ORDINARY SHARE PURCHASE WARRANT (this ?Amendment?) is effective as of April 18, 2022 by and between G Medical Innovations Holdings Ltd., a Cayman Islands exempted company (the ?Company?) and the holder of certain Warrants (as herein defined) (the ?Holder?). Each of the Company and the Holder shall be referred t |
|
| April 18, 2022 |
PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT G MEDICAL INNOVATIONS HOLDINGS LTD. EX-99.7 8 ea158539ex99-7gmedical.htm FORM OF PLACEMENT AGENT WARRANT Exhibit 99.7 [Execution Version] NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES A |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2022 (Report No. 2) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Addres |
|
| March 31, 2022 |
EX-99.1 2 ea157749ex99-1gmedicalinnov.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE G Medical Innovations (NASDAQ: GMVD) takes aggressive approach to protect shareholders by combatting naked shorting of GMVD shares with an investigation to end the criminal activity and ensure perpetrators will face aggressive legal action Poised for expansion and growth, the company continues to process thou |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2022 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Address of principal |
|
| March 1, 2022 |
Exhibit 99.1 G Medical Innovations? G Medical Tests and Services to Expand COVID-19 Testing to 150+ Additional Locations Across California via a $5.2 Million Cash Purchase The new sites will enable processing of more than 200,000 COVID-19 PCR and rapid antigen/flu tests, with anticipated revenues of $20 million over the next several months - with longer-term growth expected via direct-to-consumer |
|
| February 23, 2022 |
G Medical Innovations Holdings Ltd. 5 Oppenheimer Street Rehovot, 7670105, Israel G Medical Innovations Holdings Ltd. 5 Oppenheimer Street Rehovot, 7670105, Israel February 23, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: G Medical Innovations Holdings Ltd. (CIK 0001760764) Registration Statement No. 333-262422 on Form F-1 (the ?Registration Statement?) Ladies and Gentlemen: G Medical Innovations H |
|
| February 23, 2022 |
G Medical Innovations Holdings Ltd. 5 Oppenheimer Street Rehovot, 7670105, Israel G Medical Innovations Holdings Ltd. 5 Oppenheimer Street Rehovot, 7670105, Israel February 23, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: G Medical Innovations Holdings Ltd. (CIK 0001760764) Registration Statement No. 333-262724 on Form F-1 (the ?Registration Statement?) Ladies and Gentlemen: G Medical Innovations H |
|
| February 22, 2022 |
GMVD / G Medical Innovations Holdings Ltd. / Geva Yacov - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* G Medical Innovations Holdings Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.09 per share (Title of Class of Securities) G39462208 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2022 (Report No. 4) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Add |
|
| February 16, 2022 |
EX-99.1 2 ea155835ex99-1gmedical.htm PRESS RELEASE TITLED: "G MEDICAL INNOVATIONS ANNOUNCES THAT MORE THAN 200,000 LIVENOW AT-HOME COVID-19 PCR TESTS ARE NOW AVAILABLE AT 4,000+ CIRCLE K LOCATIONS NATIONALLY, WITH 300,000 MORE TO SHIP IN THE COMING WEEKS." Exhibit 99.1 G Medical Innovations Announces that More than 200,000 LiveNow At-Home COVID-19 PCR Tests are Now Available at 4,000+ Circle K Loc |
|
| February 15, 2022 |
As filed with the Securities and Exchange Commission on February 15, 2022. As filed with the Securities and Exchange Commission on February 15, 2022. Registration No. 333-262422 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Amendment No. 1 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 G MEDICAL INNOVATIONS HOLDINGS LTD. (Exact name of registrant as specified in its charter) Cayman Islands 3841 Not Applicable (State or other j |
|
| February 14, 2022 |
Power of Attorney (included on the signature page of the Registration Statement). As filed with the Securities and Exchange Commission on February 14, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 G MEDICAL INNOVATIONS HOLDINGS LTD. (Exact name of registrant as specified in its charter) Cayman Islands 3841 Not Applicable (State or other jurisdiction of incorporat |
|
| February 14, 2022 |
Calculation of Filing Fee Tables. Exhibit 107 Calculation of Filing Fee Tables FORM F-1 ………….. (Form Type) G MEDICAL INNOVATIONS HOLDINGS LTD. ……………………………………………………..… (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate |
|
| February 7, 2022 |
Exhibit 99.1 G Medical Innovations (NASDAQ: GMVD) to Open One of the Largest COVID-19 Test Processing Labs and Walk-in Testing Facilities in the U.S. The 26,000 sq ft site in Laguna, CA opens next week and will be able to process approximately 100,000 tests daily Laguna, CA ? February 7, 2022 ? G Medical Innovations Holdings Ltd. (NASDAQ: GMVD), a telehealth, medical device, and remote patient mon |
|
| February 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2022 (Report No. 3) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Add |
|
| February 3, 2022 |
Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of February 1, 2022, between G Medical Innovations Holdings Ltd., a Cayman Islands exempted company (the ?Company?), and each purchaser identified on the signature page hereto (including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the t |
|
| February 3, 2022 |
ORDINARY SHARE PURCHASE WARRANT G MEDICAL INNOVATIONS HOLDINGS LTD. Exhibit 99.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| February 3, 2022 |
AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT Exhibit 99.3 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This Amended and Restated Registration Rights Agreement (this ?Agreement?) is made and entered into as of February 1, 2022, between G Medical Innovations Holdings Ltd., a Cayman Islands exempted company (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purc |
|
| February 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2022 (Report No. 2) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Add |
|
| February 1, 2022 |
PRE-FUNDED PURCHASE WARRANT G MEDICAL INNOVATIONS HOLDINGS LTD. Exhibit 99.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| February 1, 2022 |
[The remainder of this page has been intentionally left blank.] EX-99.4 5 ea154683ex99-4gmedical.htm PLACEMENT AGENCY AGREEMENT Exhibit 99.4 January 30, 2022 G Medical Innovations Ltd. 5 Oppenheimer St. Rehovot 7670105 Israel Attention: Dr. Yacov Geva Dear Dr. Geva: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and G Medical Innovations Holdings Ltd., a Cayman Islands exempted company (t |
|
| February 1, 2022 |
EX-99.2 3 ea154683ex99-2gmedical.htm SECURITIES PURCHASE AGREEMENT Exhibit 99.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 30, 2022, between G Medical Innovations Holdings Ltd., a Cayman Islands exempted company (the “Company”), and each purchaser identified on the signature page hereto (including its successors and assigns, a “Purcha |
|
| February 1, 2022 |
ORDINARY SHARE PURCHASE WARRANT G MEDICAL INNOVATIONS HOLDINGS LTD. Exhibit 99.6 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| February 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2022 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Address of princip |
|
| February 1, 2022 |
EX-99.3 4 ea154683ex99-3gmedical.htm REGISTRATION RIGHTS AGREEMENT Exhibit 99.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 30, 2022, between G Medical Innovations Holdings Ltd., a Cayman Islands exempted company (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and |
|
| February 1, 2022 |
PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT G MEDICAL INNOVATIONS HOLDINGS LTD. Exhibit 99.7 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| February 1, 2022 |
G Medical Innovations Holdings Ltd Announces $12 Million Private Placement Exhibit 99.1 G Medical Innovations Holdings Ltd Announces $12 Million Private Placement TEL AVIV and NEW YORK, January 31, 2022 (GLOBE NEWSWIRE) ? G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the ?Company?), a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, today announced |
|
| January 31, 2022 |
6-K 1 ea154612-6kgmedicalinnov.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2022 (Report No. 5) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant’ |
|
| January 31, 2022 |
Calculation of Filing Fee Tables. EX-FILING FEES 6 ea154535ex-feesgmedical.htm FILING FEE TABLE Exhibit 107 Calculation of Filing Fee Tables FORM F-1 ………….. (Form Type) G MEDICAL INNOVATIONS HOLDINGS LTD. ……………………………………………………..… (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) |
|
| January 31, 2022 |
Exhibit 21.1 LIST OF SUBSIDIARIES Company Name Jurisdiction of Incorporation Jurisdiction of Incorporation G Medical Innovations Ltd. Israel G Medical Innovations USA Inc. Delaware G Medical Innovations MK Ltd. Macedonia G Medical Innovations Asia Limited Hong Kong Telehrythmics LLC Tennessee G Medical Mobile Health Solutions, Inc. Illinois G Medical Diagnostics Services, Inc. Texas G Medical Inno |
|
| January 31, 2022 |
Power of Attorney (included on the signature page of the Registration Statement). As filed with the Securities and Exchange Commission on January 31, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 G MEDICAL INNOVATIONS HOLDINGS LTD. (Exact name of registrant as specified in its charter) Cayman Islands 3841 Not Applicable (State or other jurisdiction of incorporati |
|
| January 31, 2022 |
EX-10.39 3 ea154535ex10-39gmedical.htm JOINT DEVELOPMENT, LICENSING AND DISTRIBUTION AGREEMENT BETWEEN THE COMPANY AND HEARTBUDS AK, LLC., DATED NOVEMBER 30, 2021 Exhibit 10.39 JOINT DEVELOPMENT, LICENSING AND DISTRIBUTION AGREEMENT This JOINT DEVELOPMENT, LICENSING AND DISTRIBUTION AGREEMENT (this “Agreement”) is entered into as of this 30 day of November 2021 (the “Effective Date”), by and betwe |
|
| January 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2022 (Report No. 4) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Addr |
|
| January 27, 2022 |
Exhibit 99.1 G Medical Innovations Joins Forces with Serology Covid Testing to Support Safer Classroom Learning in California School Districts Amid Omicron Variant Surge On average, G Medical expects to collect an average of $197.88 per patient encounter, which could amount to more than $1,000,000 in gross revenue per week January 25, 2022, G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (?G Med |
|
| January 19, 2022 |
EX-99.1 2 ea154216ex99-1gmedical.htm PRESS RELEASE Exhibit 99.1 G Medical Innovations (NASDAQ: GMVD) is forecasting incremental Q1 revenues at around $30 MM, based on revenue generated from G Medical Tests and Services’ physical storefront testing locations McDade Products, LLC and G Medical Innovations announce personal acquisitions of G Medical shares in the open market PITTSBURGH, PA – January |
|
| January 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2022 (Report No. 3) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Addr |
|
| January 19, 2022 |
EX-99.2 3 ea154216ex99-2gmedical.htm PRESS RELEASE Exhibit 99.2 Correction Notice to Press Release Regarding Personal Acquisitions of G Medical Shares in the Open Market TEL AVIV and Pittsburgh, January 18, 2022, McDade Products, LLC and G Medical Tests and Services, a division of G Medical Innovations Holdings Ltd (NASDAQ: GMVD), announced today a correction to their press release issued January |
|
| January 12, 2022 |
Exhibit 99.1 McDade Products, LLC and G Medical Tests Secure Additional Purchase Order for $6.5 Million, Reflecting $3.5 Million Gross Margin, to be Delivered in Q1 G Medical Expands COVID-19 Testing Portfolio in Response to Omicron Variant, Distributes At-Home PCR Test Kits to Retail Stores Nationwide PITTSBURGH, PA ? January 12, 2022 ?McDade Products, LLC and G Medical Tests and Services, a divi |
|
| January 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2022 (Report No. 2) Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Addr |
|
| January 10, 2022 |
Exhibit 99.1 McDade Products, LLC Joins Forces with G Medical Tests and Services to Provide U.S. Retailers with Millions of COVID-19 at-Home PCR Test Kits Initial Purchase Order for $13 Million, Reflecting $7 Million Gross Margin, to be Delivered in Q1 FDA EUA-approved PCR collection kit tests provide 24-hour certified lab results and retail for $9.99 PITTSBURGH, PA ? January 2022 ? In response to |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2022 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Address of principa |
|
| December 16, 2021 |
EX-4.1 2 ea152490ex4-1gmedicalin.htm FORM OF WARRANT Exhibit 4.1 Execution Version THIS WARRANT HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| December 16, 2021 |
Press release dated December 16, 2021. EX-10.3 5 ea152490ex10-3gmedicalin.htm PRESS RELEASE DATED DECEMBER 16, 2021 Exhibit 10.3 Lind to Provide $5M to Boost Prizma Sales to the Growth in Demand for Covid-19 Testing Across California TEL AVIV and NEW YORK, Dec. 16, 2021 G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) (the “Company”) today announced the closing of a private placement in the form of a convertible note in the principal |
|
| December 16, 2021 |
EX-10.1 3 ea152490ex10-1gmedicalin.htm SECURITIES PURCHASE AGREEMENT, DATED AS OF DECEMBER 15, 2021, BY AND BETWEEN THE COMPANY AND LIND Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (as amended, supplemented, restated and/or modified from time to time, this “Agreement”) is entered into as of December 15, 2021, by and between G Medical Innovations |
|
| December 16, 2021 |
Exhibit 10.2 Execution Version [THIS NOTE HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PUR |
|
| December 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2021 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Address of princip |
|
| September 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2021 Commission file number: 001-39674 G MEDICAL INNOVATIONS HOLDINGS LTD. (Translation of registrant?s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Address of princi |
|
| September 15, 2021 |
Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS For the Six Months Ended June 30, 2021 Cautionary Statement Regarding Forward-Looking Statements Certain information included herein may be deemed to be ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Forward-looking s |
|
| September 15, 2021 |
Exhibit 99.3 G Medical Innovations Holdings Ltd. Reports Financial Results for the Six Months Ended June 30, 2021, with Revenue up 45.5% ? Demand for patient monitoring services recovering with revenue increasing 45.5% in first half of 2021 ? Accelerating growth strategy with expansion of Prizma and Cardiac sales team ? UnityPoint Prizma vital signs pilot study to start end of September; new cardi |
|
| September 15, 2021 |
G Medical Innovations Holdings Ltd. Exhibit 99.1 G Medical Innovations Holdings Ltd. Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2021 Table of Contents Unaudited Condensed Consolidated Interim Financial Statements: Page Unaudited Interim Condensed Consolidated Statements of Financial Position 2 Unaudited Interim Condensed Consolidated Statements of Loss and Other Comprehensive Loss 3 Unaudited Interi |
|
| June 29, 2021 |
G Medical Innovations Holdings Ltd. Announces Closing of $15.0 Million Initial Public Offering EX-99.1 2 ea143505ex99-1gmedical.htm PRESS RELEASE TITLED: "G MEDICAL INNOVATIONS HOLDINGS LTD. ANNOUNCES CLOSING OF $15.0 MILLION INITIAL PUBLIC OFFERING." Exhibit 99.1 G Medical Innovations Holdings Ltd. Announces Closing of $15.0 Million Initial Public Offering TEL AVIV and NEW YORK , June 29, 2021 (GLOBE NEWSWIRE) - G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company"), a telehealt |
|
| June 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2021 Commission file number: 001-39674 G Medical Innovations Holdings Ltd. (Translation of registrant?s name into English) 5 Oppenheimer St. Rehovot 7670105, Israel (Address of principal e |
|
| June 28, 2021 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-253852 PROSPECTUS 3,000,000 Units (each consisting of one Ordinary Share and one Warrant to purchase one Ordinary Share) G Medical Innovations Holdings Ltd. This is the initial public offering in the United States of G Medical Innovations Holdings Ltd., a Cayman Islands exempted company. We are offering 3,000,000 units (or Units) each consistin |
|
| June 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 G MEDICAL INNOVATIONS HOLDINGS LTD. (Exact name of registrant as specified in its charter) Cayman Islands Not Applicable (State of incorporation or organization) (I.R.S. Employer Identification No. |
|
| June 22, 2021 |
June 22, 2021 Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: G Medical Innovations Holdings Ltd. Registration Statement on Form F-1 File No. 333-253852 VIA EDGAR Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, EF Hutton, division of Benchmark |
|
| June 22, 2021 |
G Medical Innovations HOLDINGS Ltd. 5 Oppenheimer St., Rehovot Israel, 7670105 G Medical Innovations HOLDINGS Ltd. 5 Oppenheimer St., Rehovot Israel, 7670105 June 22, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: G Medical Innovations Holdings Ltd. (CIK 0001760764) Registration Statement on Form F-1, as amended (the ?Registration Statement?) File No. 333-253852 Request for Acceleration of Effecti |
|
| June 15, 2021 |
EX-1.1 2 ea142684ex1-1gmedical.htm FORM OF UNDERWRITING AGREEMENT BY AND AMONG G MEDICAL INNOVATIONS HOLDINGS LTD Exhibit 1.1 UNDERWRITING AGREEMENT between G MEDICAL INNOVATIONS HOLDINGS LTD. and EF HUTTON, division of Benchmark Investments, LLC, as Representative of the Several Underwriters G MEDICAL INNOVATIONS HOLDINGS LTD. UNDERWRITING AGREEMENT New York, New York [●], 2021 EF HUTTON, divisio |
|
| June 15, 2021 |
As filed with the Securities and Exchange Commission on June 15, 2021 As filed with the Securities and Exchange Commission on June 15, 2021 Registration No. |
|
| June 15, 2021 |
Form of Warrant Certificate (included in Exhibit 4.2). Exhibit 4.2 WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of April , 2021 (the “Issuance Date”) between G Medical Innovations Holdings Ltd., a Cayman Islands exempted company (the “Company”), and VStock Transfer, LLC (the “Warrant Agent”). WHEREAS, pursuant to the terms of that certain Underwriting Agreement (“Underwriting Agreement”), dated June , 2021, by an |
|
| June 15, 2021 |
Exhibit 3.1 THE COMPANIES LAW (AS REVISED) OF THE CAYMAN ISLANDS EXEMPTED COMPANY LIMITED BY SHARES MEMORANDUM AND ARTICLES OF ASSOCIATION OF G MEDICAL INNOVATIONS HOLDINGS LTD. (adopted by Special Resolution passed on 25 MARCH 2021) www.verify.gov.ky File#: 291079 Filed: 22-Apr-2021 09:27 EST Auth Code: G65243877354 THE COMPANIES LAW (AS REVISED) OF THE CAYMAN ISLANDS EXEMPTED COMPANY LIMITED BY |
|
| June 11, 2021 |
Our Mobile Devices and Data Monitoring Reduce Healthcare Costs and Improve Quality of Care MEDICAL JUNE 2021 INVESTOR PRESENTATION Issuer Free Writing Prospectus Dated June 11, 2021 Filed Pursuant to Rule 433 Relating To Preliminary Prospectus Dated June 8, 2021 Registration Statement No. |
|
| June 9, 2021 |
As filed with the Securities and Exchange Commission on June 8, 2021 As filed with the Securities and Exchange Commission on June 8, 2021 Registration No. |
|
| April 22, 2021 |
Exhibit 10.36 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 7, 2021, between G Medical Innovations Holdings Ltd., a Cayman Islands corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the t |
|
| April 22, 2021 |
As filed with the Securities and Exchange Commission on April 21, 2021 Registration No. |
